ReShape Lifesciences has patented a system for inflating intragastric devices to treat obesity. The system includes an inflation fluid container, intragastric balloon, fluid pathway, valve, pressure gauge, and computing device to monitor and control the inflation process. GlobalData’s report on ReShape Lifesciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights ReShape Lifesciences Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on ReShape Lifesciences, Ostomy monitoring system was a key innovation area identified from patents. ReShape Lifesciences's grant share as of January 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.

Inflatable intragastric device system for treating obesity

Source: United States Patent and Trademark Office (USPTO). Credit: ReShape Lifesciences Inc

The granted patent (Publication Number: US11819433B2) describes a system for performing an inflation procedure to inflate an inflatable intragastric device. The system includes an inflation fluid container, an inflatable intragastric balloon, a fluid pathway connecting the container and the balloon, valves to control the gas flow, a pressure gauge to measure balloon pressure, and a computing device to provide instructions to the valves based on pressure measurements. The computing device can determine if the balloon is in a constrained or unconstrained space based on pressure readings, adjust inflation fluid volume, compare pressure to target values, and provide fail-safe instructions to the user.

Furthermore, the system can distinguish between different constrained spaces, compare pressure measurements to safety criteria, and determine if the balloon is filled. The processing unit can also vent excess inflation fluid, provide alerts for constrained space location, and determine the amount of inflation fluid needed to achieve a target pressure within the balloon. The system aims to ensure safe and accurate inflation of the intragastric device, with specific pressure thresholds and fail-safe procedures in place. The use of SF6 and nitrogen as inflation fluids is also highlighted in the patent claims, emphasizing the importance of precise control and monitoring during the inflation process to prevent damage to the device or surrounding tissues.

To know more about GlobalData’s detailed insights on ReShape Lifesciences, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.